BMC Infectious Diseases

Table 2 Antifungal susceptibilities of 242 Candida albicans isolates

From: Incidence, susceptibility and outcomes of candidemia in adults living in Calgary, Alberta, Canada (2010–2018)

Methodology	Antifungal	No.	MIC⁵⁰	MIC⁹⁰	Susceptible	Resistant
			(µg/mL)	(µg/mL)	(%)	(%)	95% CI
CLSI	Caspofungin	241	0.06	0.12	99.6	0.4	0.0–2.3
Breakpoints	Micafungin	190	0.008	0.016	100	0	0.0–1.9
	Voriconazole	241	0.008	0.015	97.9	2.1	0.7–4.8
	Fluconazole	242	0.5	1	97.5	2.5	0.9–5.3

		No.	MIC⁵⁰	MIC⁹⁰	WT¹	NWT²	95% CI
			(µg/mL)	(µg/mL)	(%)	(%)
CLSI	Amphotericin B	242	0.5	0.5	100	0	0.0–1.5
ECV³	Posaconazole	125	0.03	0.06	90.5	9.5	5.1–16.2

¹Wild type
²Non-wild type
³Epidemiological cut-off value

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com